Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of relapsing-remitting MS (RRMS) or relapsing secondary progressive MS (SPMS)
Neurologically stable at Screening, in the investigator's judgment and not actively experiencing or recovering from a recent relapse in the 30 days preceding the Screening Visit
A Kurtzke Expanded Disability Status Scale (EDSS) score of 1.0 to 6.0, inclusive at the Screening Visit
High or mixed affinity binder of the TSPO, as determined by rs6971 polymorphism genotyping at screening
You may not be if
Diagnosis of primary progressive or non-relapsing secondary progressive MS
Smoking more than 10 cigarettes per day or use of a nicotine patch
Known history of, or positive screening test result for hepatitis C virus or hepatitis B virus
Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before Screening
Any type of live virus vaccine from 4 weeks before randomization
History of abnormal laboratory results
Clareo Health | [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis
